*Sponsored by Modular Medical Inc
MODD’s Pivot™️ is a removable two-part design tubeless patch pump with a 3 mL reservoir, intuitive interface, and flexible, wearable form factor support everyday activities, such as showering and sports, with no battery recharging required – all while maintaining clinical accuracy and connectivity
The “Almost-Pumpers” Finally Have a Device Built for Them — And the Company Behind It Just Cleared Its Biggest Hurdle
FDA Cleared, Launch Imminent: Why This Under-the-Radar Diabetes Device Company Could Be the Most Important Medical Device Story of Fall 2026
CHECK OUT THE INVESTOR PRESENTATION
Hello Everyone,
There’s a quiet revolution unfolding in the world of diabetes care, and it’s not coming from a biotech giant with a billion-dollar R&D budget. It’s coming from a lean, focused medical device company headquartered in San Diego, California, that spent years engineering a single answer to one of healthcare’s most persistent questions: why do roughly 70% of insulin-dependent adults still rely on daily injections when pump technology has existed for decades?
The answer, as Modular Medical, Inc. (Nasdaq: MODD) identified early on, came down to what CEO Jeb Besser calls the “three Cs” — complexity, cumbersomeness, and cost. Traditional insulin pumps, while effective, have long carried a barrier to entry that kept millions of potential users on the sidelines. These are the “almost-pumpers,” adults living with Type 1 or Type 2 diabetes who want better outcomes but have been priced out, intimidated out, or simply turned off by what was available. That calculation may be changing.
The company just dropped some substantial news this week that is still in play: The Pivot tubeless insulin patch pump is now commercially available in the U.S. following FDA 510(k) clearance in April Pivot represents a differentiated solution for insulin-dependent adults still on multiple daily injections, representing a multi-billion-dollar market with Commercial expansion activities expected to begin in Q4 2026.
Before diving into the full story, here is why MODD is drawing attention right now. One of the most significant de-risking events in any medical device company’s lifecycle arrived on April 9th, 2026 for MODD, when the FDA granted 510(k) clearance for the Pivot™️ tubeless insulin patch pump. The Pivot is the first two-part tubeless patch pump featuring a removable 3 mL reservoir, disposable battery, smartphone connectivity for bolus and monitoring, and true electronic accuracy without tubes or constant wear, giving MODD a potential first-mover position in a segment that has never had a device like this. The “almost-pumper” segment — roughly 70% of insulin-dependent adults still on daily injections — represents an estimated $3 billion addressable market that MODD is now commercially cleared to pursue. With commercial launch targeted for fall 2026 and initial patients expected soon, MODD is entering its most operationally consequential period since the company’s founding. With Yahoo Finance reporting a float of approximately 2.22 million shares, there is strong potential for significant volatility on a daily basis. And the May 2025 addition of Jeff Goldberg — a veteran of Alfred E. Mann’s medical device incubator and current Chairman of Lannett Company — brought meaningful experience in drug-device combinations and affordable insulin delivery directly to the MODD board.
On April 9th, 2026, Modular Medical received U.S. Food and Drug Administration 510(k) clearance for its next-generation Pivot™ tubeless insulin patch pump, a device the company describes as the first two-part removable tubeless patch pump designed specifically for this overlooked patient population. Within weeks, the company launched PivotPump.com, a patient-facing digital hub designed to guide potential users through their options. Commercial launch is targeted for the fall of 2026. For market watchers who track medical device names in pre-commercial or early-commercial phases, this is precisely the kind of inflection point that tends to draw attention before the broader conversation catches up. MODD has cleared its most significant regulatory hurdle. The next chapter is execution.
The Pivot™ is not simply an incremental improvement on existing patch pumps. It is structured as a two-part system: a reusable pump body paired with a disposable 3 mL reservoir and battery. This design allows the wearer to remove the pump for showering, sports, or discretion — a feature no other tubeless patch pump currently on the market offers in this configuration. It also delivers electronic dosing accuracy without tubing, constant wear requirements, or a separate handheld controller. Smartphone connectivity for bolus delivery and real-time monitoring is built in. Software enhancements already in the pipeline include variable bolus options, improved alarm systems, and compatibility with automated closed-loop insulin delivery systems, a feature set that positions Pivot as a potential gateway device into the growing automated insulin delivery ecosystem.
Modular Medical has consistently framed its commercial target as the “almost-pumper” segment, a term that captures approximately 70% of insulin-dependent adults who remain on multiple daily injections despite qualifying as candidates for pump therapy. The company estimates the addressable market at approximately $3 billion. The case for this segment is built on clinical logic as much as commercial math. Research consistently shows that pump therapy can improve long-term glycemic outcomes and potentially reduce downstream healthcare costs, yet barriers to adoption have kept the majority of eligible patients on injections. A device that directly targets affordability, simplicity, and wearability addresses those specific friction points without asking patients to compromise on clinical outcomes.
Modular Medical’s manufacturing platform was deliberately engineered from the ground up for high-volume, low-cost production — a design decision that is now paying dividends. The company completed its MODD1 cartridge production run at over 6,000 units prior to transitioning the line to Pivot production. Validation production lots for both the Pivot cartridge and infusion set were reported underway by early 2026. Initial production capacity targets approximately 6,000 users, with the platform designed for rapid scaling as commercial demand materializes.
When FDA clearance arrived, CEO Jeb Besser didn’t reach for corporate boilerplate. His public statement was direct, and it told a specific story about years of focused engineering work reaching its intended destination. “FDA clearance for Pivot represents years of focused innovation to deliver a truly differentiated tubeless patch pump. By addressing the key barriers — complexity, bulkiness, and cost — Pivot gives ‘almost-pumpers’ a reason to finally make the switch. We’re excited to begin getting this technology into the hands of patients who have been waiting for something different.” That framing — “a reason to finally make the switch” — is not incidental language. It reflects Modular Medical’s core commercial thesis: that the market failure in pump adoption was not about clinical need or patient desire, but about product-market fit. The three Cs the company identified were not just engineering targets. They were the barriers that prior device generations failed to adequately address.
Earlier, in August 2025 at the Association of Diabetes Care & Education Specialists conference in Phoenix, Besser had introduced the Pivot’s gamified training module developed in collaboration with Level Ex, the creators of Level One, a diabetes management game endorsed by Breakthrough T1D. The move signaled that Modular Medical was thinking about the full patient adoption curve, not just device clearance. Getting a patient to try a pump is only the first step. Keeping them engaged with it is the harder problem, and one the company appears to be approaching with unconventional thinking.
For much of its public history, Modular Medical operated as a development-stage company — a classification that carries a specific kind of market skepticism. Development-stage medical device companies are evaluated on milestones, not revenue, and the finish line always seems to be one regulatory cycle away. That chapter is now closing. With FDA 510(k) clearance secured and PivotPump.com live, Modular Medical has moved the focus of its story from “when will it be cleared” to “how quickly can it scale.”
The fall 2026 commercial launch window is now the central timeline event for this company’s story. Initial patients were expected to begin using the system as of June 2026. CE Mark certification, targeting the European market, is penciled in for Q4 2026 to Q1 2027. Software roadmap updates, including automated insulin delivery compatibility, are actively in development. The commercialization architecture also appears deliberately lean. Rather than building an internal sales force from scratch, the company’s design and pricing approach targets affordability as a market access strategy, potentially reducing the friction of institutional and payer negotiations that often bog down medical device rollouts. PivotPump.com represents the patient-facing front of that strategy — a direct-to-consumer signal that Modular Medical is thinking about the full funnel: from awareness, to education, to adoption. For an under-the-radar medical device company targeting an underserved patient segment, that kind of digital infrastructure early in the commercialization arc is a detail worth noting.
NEWS
8 hours ago
Modular Medical Launches New Website for Pivot Tubeless Insulin Patch Pump
Jun 4, 2026
Apr 29, 2026
Modular Medical Announces Pricing of $3.4 Million Registered Direct Offering of Common Stock
Apr 19, 2026
Modular Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement
Apr 16, 2026
Modular Medical Receives FDA 510(k) Clearance for Pivot Tubeless Insulin Patch Pump
Apr 9, 2026
Modular Medical Announces 1-for-30 Reverse Stock Split
Mar 26, 2026
Modular Medical Announces $12.0 Million Public Offering Priced at a Premium to Market
Mar 3, 2026
Modular Medical Achieves Key Manufacturing Milestone for Pivot Tubeless Insulin Patch Pump
Feb 4, 2026
Modular Medical Receives 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Rule
Dec 31, 2025
MANAGEMENT
SINCERELY,
DISCLAIMER
MicroCapAlerts.io is owned by Dedicated Investors, LLC who is a publisher (the “Publisher”) of favorable information (the “Information”) about publicly traded companies (collectively the “Issuers”) listed on the NASDAQ Stock Exchange (“NASDAQ”), New York Stock Exchange (“NYSE”) and the OTC Markets is a paid advertisement. The Publisher lists its specific compensation at the bottom of this Disclaimer.
The Persons who pay us (“Paying Party”) to publish the Information and their affiliates may hold and control a significant amount of the public float and believe that if potential investors receive favorable information about the Issuers, investors will purchase the Issuers’ shares, including the shares that the Paying Party wants to sell. The Information is neither a solicitation to buy nor an offer to sell securities. The Information is not intended to be used as a source of information for making an investment decision. The Information is not intended and should not be used for trading or investment purposes.
Because the Publisher is paid to disseminate the Information to the public, the Publisher is required by the securities laws, including Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose certain information to you regarding its compensation, including the nature and amount of compensation. The Paying Party and its affiliates may engage in buying and selling of the Issuers’ securities before, during and after the Publication of the Information.
The Information provides de minimis information about the Issuers and is only a brief favorable snapshot of the Issuers subject to the Information. The Information consists of only positive content and does not include any negative information about the Issuers whatsoever; accordingly, you should consider the Information to be one-sided and not balanced, complete, accurate, truthful or reliable. The Publisher is not liable for your use of the Information or any success or failure that is directly or indirectly related to your use of the Information, including misinformation, omissions, errors or delays in providing or updating the Information, or for any actions taken by third parties in reliance upon the Information.
The Publisher is not objective or independent, and its publishing of the Information involves actual and material conflicts of interest, including: (i) the Publisher is paid to publish favorable information about the Issuers; (ii) the Publisher does not publish negative information because it is not paid to do so; and (iii) the Publisher is paid to publish the (favorable) Information about the Issuers advising others, including you, to purchase the Issuers’ securities; and while doing so, the Paying Party may plan to sell their shares of the Issuers.
The Information published by the Publisher may recommend that investors buy the Issuers’ shares while the Paying Party and/or their affiliates sell their shares of the Issuers. When the Paying Party sells their shares, the Issuers’ stock price may decline and thereby dramatically reduce the price at which investors can sell their shares. As such, investors who purchase the Issuers’ shares during the Publication of the Information will likely pay inflated prices. The Paying Party may sell the Issuers’ securities for less than the target prices set forth in the Information. The Paying Party and its affiliates may make substantial profits by selling their securities during the Publication of the Information while investors experience losses.
The Publisher makes no warranty or representation about the Information, including its completeness, accuracy, truthfulness or reliability, and disclaims, expressly and impliedly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the information is at your own risk. The Information is provided “as is” without any warranties of any kind without limitation. The Publisher does not verify or confirm any portion of the Information and does not conduct any due diligence or research on any aspect of the Information, including the completeness, accuracy, truthfulness or reliability of the Information.
Investors should not rely upon the Information for any purpose and should contact a licensed investment advisor and their legal advisor and review all documents about the Issuers with the assistance of such advisors, including documents publicly filed on www.sec.gov and http://www.OTCMarkets.com to obtain information about the Issuers.
Before investing in any public company, you should conduct your own in-depth investigation with the assistance of your legal, tax and investment advisors of the Issuers’ financial condition, operations, management, products or services, trends in the industry, the Issuers’ trading history, short sale positions and risks that may be material to its business and other information you and your advisors deem material to an investment decision. This investigation should include, but not be limited to, a review of available public sources and information you receive directly from http://www.OTCMarkets.com and www.sec.gov.
The Publisher is not and does not act in the capacity of any of the following and is not qualified to do so; as such, you should not construe the Publisher’s activities as involving any of the following:
▪ An independent advisor or consultant;
▪ Providing investment advice or acting in the capacity of an investment adviser or engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal or state level;
▪ Broker-dealer activities or acting in the capacity of a registered representative or broker;
▪ Stock picker;
▪ Securities trading expert;
▪ Securities researcher or analyst;
▪ Financial planner or financial planning;
▪ Provider of stock recommendations;
▪ Provider of advice about buying and selling or holding recommendations as to specific securities; or
▪ Making an offer or sale of securities or solicitation to purchase securities.
An investment in the Issuers involves a high degree of risk and uncertainties and may be subject to extreme volume and price volatility, especially during the Publication of the Information. Favorable past performance of the Issuers does not guarantee future results. If you purchase the securities of the Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Issuers include but are not limited to the risks stated below.
▪ The Information is not a solicitation or recommendation to buy, sell or hold securities, and the Publisher does not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. The Publisher conducts no due diligence or investigation of the Information or the Issuers and does not receive any verification from any party regarding the Information.
▪ If the Publisher publishes any percentage gain of the Issuers’ share from the previous day’s close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.
▪ The Information may contain statements that Issuers’ stock price has increased over a certain period of time, which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon such information in your analysis of the present or future potential of the Issuers or its securities.
▪ The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Issuers’ future stock price or future financial performance.
▪ You may encounter difficulties determining what, if any, portions of the Information are material or nonmaterial, making it all the more imperative that you conduct your own independent investigation of the Issuers and its securities with the assistance of your legal, tax and financial advisor.
▪ If the Information states that its securities are consistent with the future economic trends or even if your independent research indicates as such, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and government may react in unforeseen ways and be affected by behavioral biases that Publisher is unable to predict; (c) human and social factors may outweigh future economic trends that Publisher states may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in such economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of fully new circumstances and situations in which uncertainty becomes reality rather than of predictive economic quality; or (f) if the trends involve a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies.
▪ The Information contains forward-looking statements, i.e., statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as expects, will, anticipates, and estimates; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Issuers with the assistance of your lawyer, tax advisor and investment advisor as well as any such forward-looking statements. Any forward-looking statements made in the Information are limited to the time period in which they are made, and the Publisher does not undertake to update forward-looking statements that may change at any time.
▪ The Information is presented only as a brief snapshot of the Issuers and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Issuers and its securities and to consult your financial, legal or other advisor(s) and avail yourself of the filings and information that may be accessed at www.sec.gov or other electronic medium, including: (a) reviewing Information and Disclosure Statements and unaudited financial reports filed with the www.otcmarkets.com; (b) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (c) investment guides at www.sec.gov and www.finra.org. You should always be concerned that the Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative signs at otcmarkets.com. You should only invest with the assistance of your attorney, lawyer and tax advisor after they have conducted exhaustive due diligence on the particular Issuer and its trading activity.
▪ The Publisher may hire third-party service providers and stock promoters to electronically disseminate live news about the Issuers, yet the Publisher has no control over the content of and does not verify the information that these service providers publish.
The Publisher or its officers, directors, owners, managers, affiliates and control persons were paid to publish the Information about the issuers identified below:
Name of Issuer: 3rd party on behalf of Modular Medical Inc
Amount of Cash Compensation: twenty two thousand five hundred usd
Period of Publication of Information: One day campaign beginning and ending on June twenty sixth twenty twenty six
Where Information is Published: MicroCapAlerts.io Website, Email Campaign, SMS Campaign, Social Media including but not limited to: Youtube, X, Tiktok, Instagram, Stock Twits, Reddit, Discord.
By reading the Information and visiting the Platform, you agree you have not relied on the Information and agree to indemnify, defend and hold the Publisher harmless from any liability for any claimed direct, indirect, incidental, punitive, or consequential damages pertaining to your receipt of the Information without limitation.